Moffitt recently made headlines by treating the world’s first patient with TCR therapy for synovial sarcoma following FDA approval. But how does TCR therapy differ from CAR T-cell therapy? Moffitt's Jose Alejandro Guevara, MD, PhD explains the distinctions between these

One of the hardest things I do in #oncology clinic is translate results from a clinical trial to the #patient in front of me. In Nature Medicine, we introduce TrialTranslator, a #machinelearning framework for individualized #cancer trial emulation. nature.com/articles/s4159…

The data science revolution is getting closer. TabPFN v2 is published in Nature: nature.com/articles/s4158… On tabular classification with up to 10k data points & 500 features, in 2.8s TabPFN on average outperforms all other methods, even when tuning them for up to 4 hours🧵1/19

Great opportunity for undergrads!

#ScienceSaturday ➡️ Immunotherapies targeting neoantigens can be effective in mediating long-term durable responses in advanced cancer patients. However, identifying these neoantigens from metastatic tumors can be logistically challenging. 🧬 In this study, investigators

One billion cells. 🚨 One incredible dataset. Together with 10x Genomics + Ultima Genomics, we’re working to deliver landmark data to train AI models, advancing research in gene function, cellular behavior + understanding of health & disease czi.co/4hBZ5kM

Off-the-shelf CAR-T is here! Our phase 1 trial in Journal of Clinical Oncology shows allogeneic CD19 CAR-T cemacabtagene ansegedleucel (cema-cel) delivers durable remissions in R/R DLBCL: 🔹42% CR rate with median CR duration 23.1 months 🔹No GVHD, ICANS, or severe CRS ascopubs.org/doi/10.1200/JC…

New #JITC article: Effector T cells under hypoxia have an altered transcriptome similar to tumor-stressed T cells found in non-responsive melanoma patients bit.ly/41hOvsq Tim Shaw 🇺🇸..🇹🇼..🇺🇸 Moffitt Cancer Center

Drug tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms biorxiv.org/content/10.110…

#MCBIOS2025 day 2 !! in beautiful Salt lake city University of Utah , theme - harnessing #artificialintelligence to transform #humanhealth. Dr. Tim Shaw Tim Shaw 🇺🇸..🇹🇼..🇺🇸 and I will be co-chairing a session on #AI for #ImmunoOncology, featuring Dr. Linghua Wang Linghua Wang, MD, PhD on her brand new

Thanks to the Kay Yow Cancer Fund we will be able to begin some exciting research challenging current treatment paradigms in ovarian cancer that will hopefully improve outcomes. Thank you so much for your generous support!

Using ROICellTrack on urothelial carcinoma, we identified distinct cancer-immune cell mixtures linked to transcriptomic & morphological signatures. Check out our recent paper with Xiaofei (Sophia) Song and Roger Li. academic.oup.com/bioinformatics… #SpatialTranscriptomics

Congratulations to Michael J. Schell, Ph.D., FASA. Well deserved! 🎉🎉🎉 #Moffitt #ASA #Biostatistics #CancerResearch

In a medical milestone, a customized base editor was developed, characterized in human and mouse cells, tested in mice, studied for safety in non-human primates, cleared by U.S. FDA for clinical trial use, manufactured as a complex with an LNP, and dosed into a baby with a severe,

RSG SE-USA presents America’s 3rd #ComputationalBiology Symposium taking place December 11–13, 2025 at the University of Florida in St. Petersburg.  This is a great chance for students to connect and plan for the future of the field!

If you’d like to present at the symposium, submissions are being accepted until Friday, August 15.  Contact and submission details are in the flyers!

Researchers have been sneaking secret messages into their papers in an effort to trick AI tools into giving them a positive peer-review report Read the full story: go.nature.com/4eVTIwC

SmartImpute is now online with Cell Reports Methods cell.com/cell-reports-m…

A recent special issue of Science explores the immune system at the molecular and cellular level and how it has evolved to govern multiple facets of human health. Learn more: scim.ag/45xh33a

#ScienceSaturday ❓ How can we turn T-cells into cancer-fighting “soldiers” without changing their DNA? ➡️ A new study in Nature Biotechnology introduces an all-RNA platform that can turn T-cell genes on or off using epigenetic CRISPR tools called CRISPRoff and CRISPRon.